Gary S. Francis

Gary S. Francis

Auto-generated profile, based on publicly available information

Gary S. Francis

Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Heart
Verified
Journal Article
Open access
PDF file
GFGary S Francis
Gary S Francis

1 November 2004 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
GFGary S. Francis
Gary S. Francis
WTW.H.Wilson Tang
W.H.Wilson Tang

1 June 2006 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Open access
PDF file
GFGary Francis
Gary Francis
The cardiorenal syndrome is not well understood, and a uniform definition is lacking. Worsening renal function as determined by a decline in creatinine clearance in patients with decompensated heart failure is an identifier of patients with this syndrome. Treatment is a challenge. Diuretic therapy is valuable in treating congestion but may worsen renal function. Patients with decompensated heart failure are often refractory to diuretics, in which case higher doses must be used or alternate methods explored to reduce salt and water.

1 September 2008 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
GFGary S. Francis
Gary S. Francis
T he use of digitalis has been plagued by controversy since its initial use by Withering in 1775. We now have much more data, 1 but it should be remembered that the Digitalis Investigator Group trial was executed when ␤-blockers were not widely used to treat heart failure. There are still many questions about where we currently stand with the use of digitalis. Specifically, when should one add digoxin to the medical regimen of a patient with heart failure symptoms? Another question that frequently arises is whether one should consider stopping digoxin in a patient referred for care who has chronic stable heart failure. I will briefly examine these 2 scenarios separately. Should One Discontinue Digoxin in a Patient With Stable Heart Failure? One should never thoughtlessly change therapy in patients who are doing well. In fact, I have tended to avoid requesting such The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

1 November 2001 in Cardiology Clinics
Verified
Journal Article
Closed access
GFGary S. Francis
Gary S. Francis
JYJames B. Young
James B. Young

19 April 2005 in JACC
Verified
Journal Article
Closed access
GFGary S. Francis
Gary S. Francis
WTW.H. Wilson Tang
W.H. Wilson Tang